Endocrinology (all articles) | Page 8 of 89 | Links Medicus Content Curation & Alerts in Medicine

Summary: A prospective, randomized, case-crossover trial studied the acute health effects of caffeinated coffee consumption in 100 ambulatory adults.

Participants were monitored using continuous electrocardiogram devices, wrist-mounted accelerometers, and ongoing glucose monitoring systems for 14 days. They received daily text messages instructing them to either consume caffeinated coffee or abstain from caffeine.

The primary outcome was the mean number of daily premature atrial contractions. Results indicated that caffeinated coffee consumption didn’t lead to significantly more daily premature atrial contractions compared to caffeine avoidance. However, it was associated with a higher number of daily premature ventricular contractions, increased daily steps, and reduced nightly sleep.

Article: Acute Effects of Coffee Consumption on Health among Ambulatory Adults – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

What to know about new research on coffee and heart risks – Associated Press

CRAVE Trials Offers Most Comprehensive Overview Yet of Impact of Coffee, Caffeine Intake – HCP Live

Acute Effects of Coffee Consumption on Health – American College of Cardiology

Dissecting coffee’s impact: high consumption lowers blood pressure, raises LDL-cholesterol

27 Mar, 2023 | 13:25h | UTC

Coffee consumption and associations with blood pressure, LDL-cholesterol and echocardiographic measures in the general population – Scientific Reports

M-A | The effect of curcumin supplementation on weight loss and anthropometric indices

27 Mar, 2023 | 13:04h | UTC

The effect of curcumin supplementation on weight loss and anthropometric indices: an umbrella review and updated meta-analyses of randomized controlled trials – American Journal of Clinical Nutrition

Phase 2 RCT | Semaglutide did not improve fibrosis in NASH-related cirrhosis

27 Mar, 2023 | 13:01h | UTC

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial – The Lancet Gastroenterology & Hepatology

Commentary: Semaglutide Well-Tolerated, But Shows Lack of Improvement in Liver Fibrosis – HCP Live

Commentary on Twitter

New research – Loomba et al – Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialhttps://t.co/qkydKMpVfO #NASH #NAFLD #cirrhosis #gitwitter #livertwitter #medtwitter @DrLoomba pic.twitter.com/2A1dylSiq3

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 17, 2023

RCT | Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause

23 Mar, 2023 | 13:01h | UTC

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter (thread – click for more)

70% of women experience hot flushes or night sweats during #menopause.

A new study investigates the role Fezolinetant, a non-hormonal treatment, could play in reducing these symptoms. https://t.co/zv4b9WU03h

— The Lancet (@TheLancet) March 15, 2023

M-A | Effects of dairy intake on markers of cardio-metabolic health in adults

23 Mar, 2023 | 12:35h | UTC

Effects of dairy intake on markers of cardio-metabolic health in adults – a systematic review with network meta-analysis – Advances in Nutrition

Commentary on Twitter

Working with results of 19 randomized controlled trials (1427 total participants), #AdvNutr review authors conclude "high dairy intake (irrespective of fat content) showed no detrimental effects on anthropometric outcomes, blood lipids and blood pressure." https://t.co/59EiLeTW6g pic.twitter.com/ApVtfmfpsL

— American Society for Nutrition Journals (@jnutritionorg) March 13, 2023

Phase 2b RCT | New oral PCSK9 inhibitor reduces LDL cholesterol by 40% to 60%

22 Mar, 2023 | 13:20h | UTC

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial – Journal of the American College of Cardiology

Commentary: Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study – TCTMD

Exploratory analysis | Hypoglycemia incidence is lower with linagliptin vs. glimepiride in patients with early type 2 DM

22 Mar, 2023 | 13:15h | UTC

Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial – Diabetes, Obesity and Metabolism

Original Study: Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial – JAMA

Review | Graves’disease in children

22 Mar, 2023 | 13:08h | UTC

Graves’ disease: moving forwards – Archives of Disease in Childhood

RCT | Effect of various dosing schedules on the pharmacokinetics of oral semaglutide

22 Mar, 2023 | 13:07h | UTC

Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects – Clinical Pharmacokinetics

RCT | Time-restricted eating not more effective than daily calorie restriction for managing nonalcoholic fatty liver disease

21 Mar, 2023 | 13:38h | UTC

Summary: The TREATY-FLD randomized clinical trial investigated the effects of time-restricted eating (TRE) versus daily calorie restriction (DCR) on intrahepatic triglyceride (IHTG) content and metabolic risk factors in patients with obesity and nonalcoholic fatty liver disease (NAFLD).

Participants were randomly assigned to either TRE (eating only between 8:00 am and 4:00 pm) or DCR (habitual meal timing) and instructed to maintain a diet of 1500 to 1800 kcal/d for men and 1200 to 1500 kcal/d for women for 12 months.

The study found that the IHTG content was reduced by 6.9% in the TRE group and 7.9% in the DCR group after 12 months, a difference that was not statistically significant. Furthermore, TRE did not produce additional benefits for reducing body weight, liver stiffness, or metabolic risk factors compared with DCR.

The study supports that the main focus of a diet for managing NAFLD is caloric restriction, which can be achieved both with a TRE strategy or without a TRE strategy with similar results.

Article: Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial – JAMA Network Open

Commentary: Time-Restricted Eating Not More Beneficial Than Calorie Restriction For Patients With NAFLD, Obesity – HCP Live

Commentary on Twitter

TREATY-FLD RCT found that time-restricted eating did not produce additional benefits for reducing intrahepatic triglyceride content, body fat and metabolic risk factors vs daily-calorie-restriction among adults with obesity and NAFLD. https://t.co/it2n4o9Th1

— JAMA Network Open (@JAMANetworkOpen) March 17, 2023

RCT | Closed-loop insulin delivery system enhances blood sugar control in young children with type 1 diabetes

20 Mar, 2023 | 13:54h | UTC

Summary: The study enrolled 102 young children between ages 2 and 5, randomized in a 2:1 ratio to either a closed-loop control system of insulin delivery (“artificial pancreas”) or a standard care comparison group. During the 13 weeks of study follow-up, participants in the artificial pancreas group spent 12% more time within their target blood glucose range compared to the standard care group.

The closed-loop group experienced two cases of severe hypoglycemia, while the standard-care group had one case. In the closed-loop group, one case of diabetic ketoacidosis occurred due to a problem with the insulin pump.

Article: Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

News Releases:

Artificial Pancreas Developed at UVA Improves Blood Sugar Control for Kids Ages 2-6, Study Finds – University of Virginia

NIH-supported trial shows artificial pancreas improves blood glucose control in young children – National Institutes of Health

Commentary on Twitter

In children 2 to younger than 6 years of age with type 1 diabetes, a closed-loop control system was associated with a greater percentage of time in the target glycemic range than standard care. https://t.co/rAOLXRNuub #pediatrics #T1D pic.twitter.com/Nzwl3aFr1w

— NEJM (@NEJM) March 17, 2023